Clinical observation of docetaxel combined with carboplatin as second-or third-line treatment for patients with advanced triple-negative breast cancer

Abstract

Objective To observe the clinical efficacy and adverse reactions of docetaxel and carboplatin 21 day regimen (TC) as second-or third-line in treatment of patients with advanced triple-negative breast cancer (ATNBC). Methods 37 ATNBC patients with anthracyclines resistance were given docetaxel 70mg/m2, the first day of intravenous drip, carboplatin AUC=5, through intravenous drip on the first day, 21 days for a course of treatment, until disease progression or not tolerated or most received six cycles of chemotherapy. Results 147 cycles of chemotherapy were completed in 37 patients, and the median chemotherapy cycle was 4 cycles.The efficacy and adverse reactions could be evaluated in all patients.Among them, complete remission (CR) in 0 patient, partial remission (PR) in 12 patients (32.43%), stable (SD) in 11 patients (29.73%), and progression(PD) in 14 patients (41.18%). The effective rate(CR+ PR) was 32.43%.The disease control rate (CR+ PR+ SD) was 62.15%, median TTP was 3.9 months (95%CI: 4-8months), and median OS was 10 months.Until the end of follow-up, there were 3 patients with no progress.The main adverse reactions were hematological toxicity (51.53%) and gastrointestinal reaction (56.76%). Conclusion TC regimen is effective and safe in the treatment of patients with ATNBC. Key words: Breast cancer; Docetaxel; Carboplatin